Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Neoplasms
Both
Colorectal Neoplasms
Trial Information
Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients
Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes
with clinical outcome, including objective response, time to progression and survival
Inclusion Criteria:
- Histologically confirmed diagnosis of colorectal cancer with available tumor tissue
and clinical data; presence of at least one measurable lesion.
Exclusion Criteria:
- Less than 3 weeks after completion of previous radiotherapy
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Association of different biomarkers with Cetuximab sensitivity
Outcome Time Frame:
Assessment every two months
Safety Issue:
No
Principal Investigator
Armando Santoro, MD
Investigator Role:
Study Director
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ICH n. 380
NCT ID:
NCT00491140
Start Date:
December 2006
Completion Date:
June 2008
Related Keywords:
- Colorectal Neoplasms
- EGFR
- KRAS
- BRAF
- MET
- IGFR1
- Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|
